FDA Infant Rice Cereal Inorganic Arsenic: HTMC Insights Original paper

Researched by:

  • Dr. Umar Aitsaam ID
    Dr. Umar Aitsaam

    User avatarClinical Pharmacist and Master’s student in Clinical Pharmacy with research interests in pharmacovigilance, behavioral interventions in mental health, and AI applications in clinical decision support. Experience includes digital health research with Bloomsbury Health (London) and pharmacovigilance practice in patient support programs. Published work covers drug awareness among healthcare providers, postpartum depression management, and patient safety reporting.

    Read More

October 30, 2025

Researched by:

  • Dr. Umar Aitsaam ID
    Dr. Umar Aitsaam

    User avatarClinical Pharmacist and Master’s student in Clinical Pharmacy with research interests in pharmacovigilance, behavioral interventions in mental health, and AI applications in clinical decision support. Experience includes digital health research with Bloomsbury Health (London) and pharmacovigilance practice in patient support programs. Published work covers drug awareness among healthcare providers, postpartum depression management, and patient safety reporting.

    Read More

Last Updated: 2025-10-30

Our team of researchers are constantly monitoring and summarizing the latest research,
and we continue to update our pages to ensure you have the most accurate information.

Note on the last update: One new meta analysis added

Dr. Umar Aitsaam

Clinical Pharmacist and Master’s student in Clinical Pharmacy with research interests in pharmacovigilance, behavioral interventions in mental health, and AI applications in clinical decision support. Experience includes digital health research with Bloomsbury Health (London) and pharmacovigilance practice in patient support programs. Published work covers drug awareness among healthcare providers, postpartum depression management, and patient safety reporting.

What was studied?

This FDA Constituent Update reported targeted surveillance of inorganic arsenic in infant rice cereal to evaluate progress toward the agency’s proposed action level and to guide risk-reduction strategies; it is best treated as an original testing report rather than a narrative review. The analysis, central to FDA infant rice cereal inorganic arsenic risk management, summarized results from 149 infant rice cereal samples collected in 2018 and compared them with historical monitoring from 2011–2013. The update also contextualized findings within the 2016 Draft Guidance proposing a 100 ppb action level and described manufacturing practices that enable lower arsenic levels. These elements together form a concise evidence base relevant to certification programs and regulatory alignment.

Who was studied?

The “subjects” were commercial infant rice cereal products marketed in the United States, encompassing both white rice and brown rice formulations collected by the FDA. The 2018 dataset comprised 149 samples tested for inorganic arsenic, with performance benchmarked against the proposed 100 ppb action level; 76% of 2018 samples met this target compared with 36% in 2011–2013. Improvements were observed in both white and brown rice cereals, with greater gains among white rice products, which generally contain lower inorganic arsenic. The products, not human participants, were the locus of measurement, aligning with market-facing compliance assessment.

Most important findings

Critical PointDetail
Action level contextThe 2016 Draft Guidance proposed a 100 ppb inorganic arsenic action level for infant rice cereal, providing a reference point for compliance evaluation.
Market performance (2018)Of 149 samples collected in 2018, 76% met the 100 ppb target, showing strong progress since earlier baselines.
Historical baseline (2011–2013)Only 36% of samples met 100 ppb in 2011–2013, highlighting a large, quantifiable improvement by 2018.
Product-type differencesBoth white and brown rice cereals improved, with white rice cereals showing the greatest gains and generally lower inorganic arsenic levels.
Feasibility driversFDA indicates the action level is achievable using good manufacturing practices, notably sourcing rice with lower inorganic arsenic.
Ongoing oversightFDA will continue to identify, target, and prioritize efforts to reduce toxic element exposure from food, implying sustained surveillance.
Consumer guidance with industry impactFDA advises variety in infant cereals and grains, which can shift demand and encourage diversification beyond rice-only offerings.

Key implications

For regulatory impacts, the data support operational feasibility of a 100 ppb threshold, strengthening the case for enforceable limits and routine oversight. Certification requirements should verify validated inorganic arsenic methods, lot-level results, and documented low-arsenic sourcing. Industry applications include supplier vetting, field origin traceability, and product portfolio mixing with non-rice grains. Research gaps include longitudinal post-2018 trends and brown rice process controls. Practical recommendations emphasize supplier contracts with arsenic specs, periodic verification testing, and transparent consumer communication aligned with the FDA infant rice cereal inorganic arsenic guidance.

Citation

U.S. Food and Drug Administration. FDA Makes Available Results from Testing of Infant Rice Cereal for Inorganic Arsenic. March 6, 2020.

Arsenic (As)

Arsenic is a naturally occurring metalloid that ranks first on the ATSDR toxic substances list. Inorganic arsenic contaminates water, rice and consumer products, and exposure is linked to cardiovascular disease, cognitive deficits, low birth weight and cancer. HMTC’s stringent certification applies ALARA principles to protect vulnerable populations.